Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Joinn Laboratories (China) Co Net Margin %?
Joinn Laboratories (China) CoSHSE:603127 +3.72%78 Net Margin % is 75.40% as of Mar. 2026, which is 191% above its 10-year median of 25.94. GuruFocus rates SHSE:603127 with a GF Score™ of 78/100 and a GF Value™ of ¥17.43 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Joinn Laboratories (China) Co ranks better than 97.54% on this metric.
The historical rank and industry rank for Joinn Laboratories (China) Co's Net Margin % or its related term are showing as below:
SHSE:603127'
s Net Margin % Range Over the Past 10 Years
Min: 3.67 Med: 25.94 Max: 47.37
Current: 29.36
SHSE:603127's Net Margin % is ranked better than 97.54% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.69
vs SHSE:603127: 29.36
Joinn Laboratories (China) Co (SHSE:603127) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Joinn Laboratories (China) Co Net Margin % Related Terms
Joinn Laboratories (China) Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603127 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) has a Net Margin % of 75.40% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Joinn Laboratories (China) Co and its competitors. This is 191% above median its historical median of 25.94. Over the past decade, Joinn Laboratories (China) Co's Net Margin % has ranged from 3.67 to 47.37. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #5 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 2.5%.
Is Joinn Laboratories (China) Co's Net Margin % too high?
Joinn Laboratories (China) Co's current Net Margin % of 75.40% is 191% above median its 10-year median of 25.94. Over the past 10 years, this metric has ranged from a low of 3.67 to a high of 47.37. Based on the distribution chart, Joinn Laboratories (China) Co ranks #5 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #5 out of 203 companies for Net Margin %. This places Joinn Laboratories (China) Co in the top 3% of its industry — outperforming the majority of peers. Historically, Joinn Laboratories (China) Co's own Net Margin % has ranged from 3.67 to 47.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Joinn Laboratories (China) Co and its competitors. Joinn Laboratories (China) Co's current Net Margin % is 75.40%, which is 191% above median its own 10-year median of 25.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.43, compared to a current price of ¥41.54 — trading 138.3% above its estimated fair value. The current Net Margin % is 75.40%, which is 191% above median its 10-year median of 25.94. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Net Margin % is 75.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
Net Margin %: 75.40% (191% above median its 10-year median of 25.94)
GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score
Get the complete analysis for SHSE:603127
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
